TY - JOUR
T1 - Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder
AU - Bobo, William Victor
AU - Bonaccorso, Stefania
AU - Jayathilake, Karuna
AU - Meltzer, Herbert Yale
PY - 2011/9/30
Y1 - 2011/9/30
N2 - Baseline body mass index (BMI), baseline BMI status (normal, overweight, obese) and early (1. month) BMI increases were tested as predictors of 6- and 12-month increases in glucose and lipid measures in 82 olanzapine (OLZ)- and 78 risperidone (RIS)-treated patients with schizophrenia, schizoaffective disorder, or bipolar disorder who participated in a 12-month randomized, prospective metabolic effects study. Baseline BMI predicted greater fasting glucose and HgbA1c levels at 12. months for both treatments. Early BMI change predicted fasting glucose levels at 6. months, but not HgbA1c or BMI, at either time point. For patients who received no concomitant mood stabilizers, early BMI change predicted 12. month HgbA1c values in the OLZ group, and 6- (but not 12-) month fasting glucose and HgbA1c values in the RIS group. Neither baseline BMI nor early BMI change consistently predicted increases in lipids with either drug. OLZ-treated patients with normal baseline BMI had greater increases in total cholesterol, triglycerides, and non-HDL-cholesterol than those who were overweight or obese. In conclusion, higher baseline BMI predicted adverse glycemic changes after 12. months with OLZ and RIS. Individuals with normal baseline BMI may be most susceptible to OLZ-induced hyperlipidosis. Frequency of metabolic screening should be independent of baseline BMI or rapid increases in BMI.
AB - Baseline body mass index (BMI), baseline BMI status (normal, overweight, obese) and early (1. month) BMI increases were tested as predictors of 6- and 12-month increases in glucose and lipid measures in 82 olanzapine (OLZ)- and 78 risperidone (RIS)-treated patients with schizophrenia, schizoaffective disorder, or bipolar disorder who participated in a 12-month randomized, prospective metabolic effects study. Baseline BMI predicted greater fasting glucose and HgbA1c levels at 12. months for both treatments. Early BMI change predicted fasting glucose levels at 6. months, but not HgbA1c or BMI, at either time point. For patients who received no concomitant mood stabilizers, early BMI change predicted 12. month HgbA1c values in the OLZ group, and 6- (but not 12-) month fasting glucose and HgbA1c values in the RIS group. Neither baseline BMI nor early BMI change consistently predicted increases in lipids with either drug. OLZ-treated patients with normal baseline BMI had greater increases in total cholesterol, triglycerides, and non-HDL-cholesterol than those who were overweight or obese. In conclusion, higher baseline BMI predicted adverse glycemic changes after 12. months with OLZ and RIS. Individuals with normal baseline BMI may be most susceptible to OLZ-induced hyperlipidosis. Frequency of metabolic screening should be independent of baseline BMI or rapid increases in BMI.
KW - Antipsychotic
KW - Body mass index
KW - Glucose
KW - Metabolic effects
KW - Triglycerides
KW - Weight gain
UR - http://www.scopus.com/inward/record.url?scp=80052795027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052795027&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2011.07.008
DO - 10.1016/j.psychres.2011.07.008
M3 - Article
C2 - 21802150
AN - SCOPUS:80052795027
SN - 0165-1781
VL - 189
SP - 200
EP - 207
JO - Psychiatry Research
JF - Psychiatry Research
IS - 2
ER -